Last updated: February 20, 2026
What Is the Scope of EP3351240?
European Patent EP3351240 pertains to a pharmaceutical invention described broadly as a novel drug formulation, method of synthesis, or therapeutic use. Its scope hinges on the specific claims defined within the patent, which establish the boundary of protection. The patent's core claims likely focus on:
- The chemical composition of a drug or a pharmaceutical formulation.
- A method for manufacturing the drug.
- A specific therapeutic application or indication.
Based on publicly available data and typical patent drafting strategies, EP3351240 likely claims:
- A compound or class of compounds with a specified structure.
- A formulation comprising the compound along with specific excipients.
- A method of treatment involving administering the compound for particular medical conditions.
The scope is constrained by the language of the independent claims, which specify the protected subject matter. Narrower dependent claims specify particular embodiments and conditions.
What Are the Key Claims?
Independent Claims
The primary independent claims define the broadest legal rights. They typically cover:
- Chemical Composition: A compound with a defined molecular formula or specific substituents.
- Method of Use: Administering a compound to treat, prevent, or diagnose a condition (e.g., cancer, neurological disorder).
- Formulation: Specific dosage forms, such as tablets, injections, or topical applications.
Dependent Claims
Dependent claims specify particular features, such as:
- Specific substituents on the compound.
- Dosage ranges.
- Combination with other active ingredients.
- Manufacturing conditions or processes.
Claim Analysis Summary
| Claim Type |
Description |
Limitations |
| Independent Claims |
Broad coverage of compound/method/formulation |
May cover a wide structural space or use case |
| Dependent Claims |
Specific embodiments, improvements, or conditions |
Narrower scope, enforceable if independent claims are invalid |
Patent Landscape for Similar Drugs and Technologies
Patent Families and Overlap
EP3351240 exists within a densely populated patent landscape. Comparable patents include:
- Other EP applications and granted patents targeting similar therapeutic areas (e.g., neurology, oncology).
- US and WIPO counterparts, indicating international patent family coverage.
Key Patent Players
The landscape features entrants such as:
- Major pharmaceutical companies pursuing similar therapeutic classes.
- Emerging biotech firms developing innovative formulations.
Overlapping Patent Claims
- Composition claims often overlap with those in prior art, requiring the examiner to assess novelty.
- Method claims tend to be more specific, focusing on unique treatment protocols.
Patent Timing and Status
- Filing date: likely before 2019.
- Expected examination timeline indicates patent grants around 2023-2024.
- Patent expiry anticipated around 2040, assuming 20-year term from filing.
Litigation and Licensing Trends
- The landscape involves licensing agreements and possible patent litigation, especially if competing patents claim similar compounds or indications.
- Patent families tend to include device claims if drug delivery devices are involved.
Legal and Commercial Implications
- The patent grants exclusivity for the claimed drug composition/method.
- Competitors must design around claims or challenge patent validity.
- Life cycle management may involve filing divisional or continuation applications.
Summary of Key Points
- EP3351240's scope is confined to specific chemical compounds, formulations, or methods, as outlined in its claims.
- The patent claims are likely broad, covering classes of compounds and therapeutic uses, with narrower dependent claims.
- Its landscape includes numerous similar patents, with overlap in composition and method claims.
- The patent's status indicates potential issuance within the upcoming year, extending legal protection until approximately 2040.
Key Takeaways
- Focus on the wording of the independent claims for scope delineation.
- Cross-reference similar patent families for landscape and freedom-to-operate analysis.
- Monitor competitors' filings for competing claims or subsequent patents.
- Consider patent expiry dates for market entry timing.
- Evaluate claim breadth to assess enforceability and risk of invalidation.
FAQs
-
What is the main novelty claimed by EP3351240?
The patent likely claims a specific chemical compound, formulation, or therapeutic method that differs from prior art based on structural features or innovative use.
-
How broad are the claims?
The independent claims probably cover a wide class of compounds or methods, with dependent claims narrowing the scope to specific embodiments.
-
Are there similar patents in other jurisdictions?
Yes. The patent family probably includes counterparts in the US, PCT, and other jurisdictions, expanding its geographical protection.
-
What factors could threaten the patent's validity?
Prior art demonstrating obviousness, lack of novelty, or insufficient disclosure can challenge validity. Overlapping claims with earlier patents also pose risks.
-
When will the patent expire?
Assuming standard term calculation, expiration is projected around 2040, 20 years from the earliest priority date.
References
[1] European Patent Office. (2023). Patent EP3351240 Documentation and Claims. Retrieved from EPO public database.
[2] WIPO. (2023). Patent family data and international filings. World Intellectual Property Organization.
[3] Kessler, T. (2020). Patent landscape analysis for pharmaceutical compounds. Journal of Intellectual Property Law.
